Amylgen is a privately owned contract research organization (CRO) offering a unique combination of validated
in vivo models and
full range testing allowing fast and predictive screening of the effects of drugs and nutriments on brain.
With an aging population, neurodegenerative & neuropsychiatric diseases, including Alzheimer’s, represent a major health crisis. A scourge for the quality of life of millions of people around the world, a colossal economic issue, a real ticking time bomb in the health system.
Our expertise is based on an innovative concept, creating a major benefit for the pharmaceutical industry and for society as a whole. A unique, confidential concept developed by Amylgen’s team that transforms years into weeks, saving valuable time to accelerate drug candidate development.
The decision support model offered by
Amylgen can be very upstream in preclinical development. Thus, the preclinical phase is boosted, shortened and facilitated. Furthermore, quick & easy decision making reduces time to market & increases business.
Thanks to background in the Industry, we guarantee satisfaction and provide our services with nonconditional high quality standards and with full awareness of time sensitive deadlines in the frame of critical phases of your product development.
Our DNA: innovation, commitment, responsibility & customer satisfaction. 4 core values that guide our daily action to better Brain Health.
Copyright© 2019 Amylgen. All rights reserved.
